SCNI Scinai Immunotherapeutics Ltd.
Fundamentals / CIK 0001611747 / USDScinai Immunotherapeutics Ltd. reported $1.31M in revenue and a net loss of $8.31M for the fiscal year ended December 31, 2025 (up 99.2% year over year), with a -202.3% gross margin and a -575.3% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open SCNI in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$1.31M +99.2% YoY
-
Operating Income FY 2025-$7.54M -575.3% margin
-
Net Income FY 2025-$8.31M -633.6% net margin
-
Diluted EPS FY 2025-- Split-adjusted
-
Free Cash Flow FY 2025-$6.05M -461.9% FCF margin
-
Cash & ST Investments Dec 31, 2025$1.66M Total debt: $1.96M
Annual revenue and net income
5 fiscal years (2021 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.31M | $658K | -- | -- | -- |
| Cost of Revenue | $3.96M | $1.24M | -- | -- | -- |
| Gross Profit | -$2.65M | -$580K | -- | -- | -- |
| Research & Development | $2.37M | $5.53M | $5.21M | $5.76M | $3.25M |
| Selling, General & Admin | $2.52M | $2.53M | $4.50M | $5.30M | $7.62M |
| Total Operating Expenses | $4.89M | $8.06M | $9.71M | $11.06M | $10.86M |
| Operating Income | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M |
| EBITDA | -$6.12M | -$6.99M | -$9.19M | -$10.50M | -$10.39M |
| Interest Expense | -- | -- | $343K | $351K | $336K |
| Net Income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M |
| Basic EPS | -- | -- | $0.00 | $0.01 | -$0.02 |
| Diluted EPS | -- | -- | $0.00 | $0.01 | -$0.02 |
| Basic Shares Outstanding | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M |
| Diluted Shares Outstanding | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2023-03-31 | 2022-03-31 |
|---|---|---|
| Research & Development | $2.00M | $1.16M |
| Operating Income | -$3.19M | -$2.62M |
| EBITDA | -$3.05M | -$2.48M |
| Net Income | -$3.52M | -$2.48M |
| Basic EPS | -$0.00 | -$0.00 |
| Diluted EPS | -$0.00 | -$0.00 |
| Basic Shares Outstanding | 1.30B | 744.7M |
| Diluted Shares Outstanding | 1.30B | 744.7M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & Cash Equivalents | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M |
| Cash & Short-Term Investments | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M |
| Accounts Receivable, Net | $73K | $83K | -- | -- | -- |
| Other Current Assets | -- | -- | $437K | $155K | -- |
| Total Current Assets | $2.05M | $2.39M | $5.45M | $14.37M | $17.84M |
| Property, Plant & Equipment, Net | $7.79M | $9.19M | $10.82M | $11.24M | $12.39M |
| Total Non-Current Assets | $9.57M | $11.06M | $12.03M | $12.70M | $14.19M |
| Total Assets | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M |
| Accounts Payable | $407K | $376K | $535K | $716K | $999K |
| Short-Term Debt | -- | -- | -- | $382K | $375K |
| Deferred Revenue (Current) | $90K | $225K | -- | -- | -- |
| Total Current Liabilities | $1.58M | $1.81M | $1.78M | $2.34M | $2.44M |
| Total Non-Current Liabilities | $1.94M | $1.67M | $20.26M | $26.49M | $28.61M |
| Total Liabilities | $3.52M | $3.47M | $22.04M | $28.83M | $31.05M |
| Total Debt (incl. Leases) | $1.96M | $1.83M | $1.19M | $764K | $1.82M |
| Retained Earnings | -$125.8M | -$117.5M | -$122.3M | -$115.8M | -$110.0M |
| Accumulated Other Comp. Income | -$1.74M | -$1.74M | -$1.74M | -$2.01M | -$2.06M |
| Total Stockholders' Equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982K |
| Total Equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-03-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $1.66M | $1.96M | $4.87M | $10.80M | $14.07M | $17.37M |
| Cash & Short-Term Investments | $1.66M | $1.96M | $4.87M | $10.80M | $14.07M | $17.37M |
| Accounts Receivable, Net | $73K | $83K | -- | -- | -- | -- |
| Other Current Assets | -- | -- | $437K | -- | $155K | -- |
| Total Current Assets | $2.05M | $2.39M | $5.45M | $11.04M | $14.37M | $17.84M |
| Property, Plant & Equipment, Net | $7.79M | $9.19M | $10.82M | $10.82M | $11.24M | $12.39M |
| Total Non-Current Assets | $9.57M | $11.06M | $12.03M | $12.25M | $12.70M | $14.19M |
| Total Assets | $11.63M | $13.45M | $17.47M | $23.29M | $27.07M | $32.04M |
| Accounts Payable | $407K | $376K | $535K | $1.31M | $716K | $999K |
| Short-Term Debt | -- | -- | -- | -- | $382K | $375K |
| Deferred Revenue (Current) | $90K | $225K | -- | -- | -- | -- |
| Total Current Liabilities | $1.58M | $1.81M | $1.78M | $2.58M | $2.34M | $2.44M |
| Total Non-Current Liabilities | $1.94M | $1.67M | $20.26M | $25.52M | $26.49M | $28.61M |
| Total Liabilities | $3.52M | $3.47M | $22.04M | $28.10M | $28.83M | $31.05M |
| Total Debt (incl. Leases) | $1.96M | $1.83M | $1.19M | $420K | $764K | $1.82M |
| Retained Earnings | -$125.8M | -$117.5M | -$122.3M | -$119.3M | -$115.8M | -$110.0M |
| Accumulated Other Comp. Income | -$1.74M | -$1.74M | -$1.74M | -$1.89M | -$2.01M | -$2.06M |
| Total Stockholders' Equity | $8.10M | $9.98M | -$4.57M | -$4.81M | -$1.76M | $982K |
| Total Equity | $8.10M | $9.98M | -$4.57M | -$4.81M | -$1.76M | $982K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Net Income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M |
| Depreciation & Amortization | $1.42M | $1.65M | $514K | $562K | $471K |
| Stock-Based Compensation | $303K | $682K | $1.14M | $1.60M | $2.76M |
| Change in Receivables | $10K | -$83K | -- | -- | -- |
| Change in Payables | $31K | -$156K | -$150K | -$175K | $3.0K |
| Operating Cash Flow | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M |
| Capital Expenditure | -$24K | -$12K | -$637K | -$836K | -$139K |
| Free Cash Flow | -$6.05M | -$6.35M | -$10.02M | -$8.10M | -$7.57M |
| Investing Cash Flow | -$24K | -$12K | -$637K | -$836K | -$139K |
| Common Stock Issued | -- | $2.00M | $139K | $932K | $21.43M |
| Financing Cash Flow | $5.77M | $3.44M | $1.09M | $6.78M | $21.43M |
| Net Change in Cash | -$284K | -$2.92M | -$9.21M | -$3.30M | $14.44M |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2023-03-31 | 2022-03-31 |
|---|---|---|
| Net Income | -$3.52M | -$2.48M |
| Depreciation & Amortization | $138K | $134K |
| Stock-Based Compensation | $252K | $485K |
| Change in Payables | $629K | $311K |
| Operating Cash Flow | -$3.06M | -$1.10M |
| Capital Expenditure | -$6.0K | -$521K |
| Free Cash Flow | -$3.06M | -$1.63M |
| Investing Cash Flow | -$6.0K | -$521K |
| Net Change in Cash | -$3.29M | -$1.99M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Gross Margin | -202.3% | -88.1% | -- | -- | -- |
| Operating Margin | -575.3% | -1312.8% | -- | -- | -- |
| Net Profit Margin | -633.6% | 728.9% | -- | -- | -- |
| Return on Equity (ROE) | -102.5% | 48.1% | -- | -- | -835.6% |
| Return on Assets (ROA) | -71.5% | 35.7% | -37.2% | -21.4% | -25.6% |
| Current Ratio | 1.30x | 1.32x | 3.06x | 6.15x | 7.30x |
| Quick Ratio | 1.09x | 1.13x | 2.74x | 6.02x | 7.11x |
| Debt to Equity | 0.24x | 0.18x | -- | -- | 1.85x |
| Revenue Growth (YoY) | +99.2% | -- | -- | -- | -- |
| Net Income Growth (YoY) | -273.2% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -60.0% | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2023-03-31 | 2022-03-31 |
|---|---|---|
| Current Ratio | 4.28x | -- |
| Quick Ratio | 4.19x | -- |